Improved beamforming performance using pulsed plane wave decomposition

A tool for calculating the beamformer setup associated with a specified pulsed acoustic field is presented. The method is named Pulsed Plane Wave Decomposition (PPWD) and is based on the decomposition of a pulsed acoustic field into a set of PPWs at a given depth. Each PPW can be propagated to the location of the elements of an array transducer by a time delay. The contribution of each propagated PPW is summed to form one time function for each array element (the BMF matrix). This approach gives the beamformer setup needed to obtain a close approximation to the desired bounded pulsed acoustic field without involving any optimization scheme. The approximation arises due to the limited size of the acoustic aperture and the spatial sampling property of the array transducer. Thus, the acoustical field can be designed according to the imaging needs. The method is demonstrated by examples in the 2D space by analytical equations, simulation, and experimental results

Performance of a vector velocity estimator

It is a well-known limitation of all commercially available scanners that only the velocity component along the propagation direction of the emitted pulse is measured, when evaluating blood velocities with ultrasound. Proposals for solving this limitation using several transducers or speckle tracking can be found in the literature, but no method with a satisfactory performance has been found that can be used in a commercial implementation. A method for estimation of the velocity vector is presented. Here an oscillation transverse to the ultrasound beam is generated, so that a transverse motion yields a change in the received signals. The method uses two ultrasound beams for sampling the in-phase and quadrature component of the lateral field, and a set of samples (in-phase and quadrature in both time and space) are taken for each pulse-echo line. These four samples are then used in an autocorrelation approach that yields both the axial and the lateral velocity, and thus the velocity ve..

EU og Ukraine: Muligheder mod øst

Siden murens fald har EU engageret sig i Ukraine. Krisen i det store land mod øst har tydeligjort hvor vigtig EUs østlige grænse er, ikke kun sikkerhedspolitisk, men også i forhold til menneskerettigheder

Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET

A combination of carboplatin and paclitaxel is often used as first line chemotherapy for treatment of ovarian cancer. Therefore the use of imaging biomarkers early after initiation of treatment to determine treatment sensitivity would be valuable in order to identify responders from non-responders. In this study we describe the non-invasive PET imaging of glucose uptake and cell proliferation using 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine (FLT) for early assessment of treatment response in a pre-clinical mouse model of human ovarian cancer treated with carboplatin and paclitaxel.In vivo uptake of FLT and FDG in human ovarian cancer xenografts in mice (A2780) was determined before treatment with carboplatin and paclitaxel (CaP) and repeated day 1, 4 and 8 after treatment start. Tracer uptake was quantified using small animal PET/CT. Tracer uptake was compared with gene expression of Ki67, TK1, GLUT1, HK1 and HK2.Tumors in the CaP group was significantly smaller than in the control group (p=0.03) on day 8. On day 4 FDG SUVmax ratio was significantly lower in the CaP group compared to the control group (105 ± 4% vs 138 ± 9%; p=0.002) and on day 8 the FDG SUVmax ratio was lower in the CaP compared to the control group (125 ± 13% vs 167 ± 13%; p=0.05). On day 1 the uptake of FLT SUVmax ratio was 89 ± 9% in the CaP group and 109 ± 6% in the control group; however the difference was not statistically significant (p=0.08).Our data suggest that both FDG and FLT PET may be used for the assessment of anti-tumor effects of a combination of carboplatin and paclitaxel in the treatment of ovarian cancer. FLT provides an early and transient signal and FDG a later and more prolonged response. This underscores the importance of optimal timing between treatment and FLT or FDG imaging since treatment response may otherwise be overlooked

Early Detection of Response to Experimental Chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice

BACKGROUND: 3'-Deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) is a tracer used to assess cell proliferation in vivo. The aim of the study was to use (18)F-FLT positron emission tomography (PET) to study treatment responses to a new anti-cancer compound. To do so, we studied early anti-proliferative effects of the experimental chemotherapy Top216 non-invasively by PET. METHODOLOGY/PRINCIPAL FINDINGS: In vivo uptake of (18)F-FLT in human ovary cancer xenografts in mice (A2780) was studied at various time points after Top216 treatment (50 mg/kg i.v. at 0 and 48 hours) was initiated. Baseline (18)F-FLT scans were made before either Top216 (n = 7-10) or vehicle (n = 5-7) was injected and repeated after 2 and 6 hours and 1 and 5 days of treatment. A parallel study was made with 2'-deoxy-2'-[(18)F]fluoro-D-glucose ((18)F-FDG) (n = 8). Tracer uptake was quantified using small animal PET/CT. Imaging results were validated by tumor volume changes and gene-expression of Ki67 and TK1. Top216 (50 mg/kg 0 and 48 hours) inhibited the growth of the A2780 tumor compared to the control group (P<0.001). (18)F-FLT uptake decreased significantly at 2 hours (-52%; P<0.001), 6 hours (-49%; P = 0.002) and Day 1 (-47%; P<0.001) after Top216 treatment. At Day 5 (18)F-FLT uptake was comparable to uptake in the control group. Uptake of (18)F-FLT was unchanged in the control group during the experiment. In the treatment group, uptake of (18)F-FDG was significantly decreased at 6 hours (-21%; P = 0.003), Day 1 (-29%; P<0.001) and Day 5 (-19%; P = 0.05) compared to baseline. CONCLUSIONS/SIGNIFICANCE: One injection with Top216 initiated a fast and significant decrease in cell-proliferation assessable by (18)F-FLT after 2 hours. The early reductions in tumor cell proliferation preceded changes in tumor size. Our data indicate that (18)F-FLT PET is promising for the early non-invasive assessment of chemotherapy effects in both drug development and for tailoring therapy in patients